Yan Hu, Wei Chen, Mostafa Gouda, Huan Yao, Xinxin Zuo, Huahao Yu, Yuying Zhang, Lejia Ding, Fengle Zhu, Yuefei Wang, Xiaoli Li, Jihong Zhou, Yong He
Fungal fermentation of Fuzhuan brick tea: A comprehensive evaluation of sensory properties using chemometrics, visible near-infrared spectroscopy, and electronic nose
Food research international (Ottawa, Ont.)
review aims evaluate safety efficacy apixaban vs vitamin k antagonists vkas patients dialysis types studies published pubmed embase central web science 10 september 2023 comparing outcomes apixaban vs vka dialysis patients eligible two randomized controlled trials rcts six retrospective studies included apixaban treatment associated significantly lower risk major bleeding rr 061 95 ci 048 077 i2 50 clinically relevant nonmajor bleeding rr 082 95 ci 068 098 i2 9 compared vka metaanalysis also showed risk gastrointestinal bleeding rr 074 95 ci 064 085 i2 16 intracranial bleeding rr 064 95 ci 049 084 i2 0 significantly reduced apixaban metaanalysis showed difference risk ischemic stroke rr 040 95 ci 006 269 i2 0 mortality rr 126 95 ci 074 216 i2 94 recurrent venous thromboembolism rr 102 95 ci 087 121 i2 0 two groups subgroup analysis rcts showed difference bleeding outcomes lowquality evidence mix rcts retrospective studies shows apixaban may better safety equivalent efficacy compared vka dialysis patients apixaban treatment correlated significantly reduced risk major bleeding clinically relevant nonmajor bleeding observational studies rcts predominance retrospective data warrants caution interpretation results